UC Irvine

UC Irvine Previously Published Works

Title

PRECLINICAL IN VIVO EVALUATION OF VASCULAR EFFECTS OF PULSED DYE LASER IN COMBINATION WITH OXYMETAZOLINE

Permalink

https://escholarship.org/uc/item/8mf8w2wq

Authors

Pai, Alex Kelly, Alexis Lertsakdadet, Ben et al.

Publication Date

2019

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed

S12 American Society for Laser Medicine and Surgery Abstracts

PRECLINICAL *IN VIVO* EVALUATION OF VASCULAR EFFECTS OF PULSED DYE LASER IN COMBINATION WITH OXYMETAZOLINE Alex Pai, Alexis Kelly, Ben Lertsakdadet, Bernard Choi, Kristen M. Kelly

University of California – Irvine, Irvine, CA

Background: Oxymetazoline is a medication with vascular effect approved for topical treatment of persistent facial erythema associated with rosacea. Due to the dynamic effect of this agent on the vasculature, oxymetazoline may be a useful adjunct for pulsed dye laser (PDL) treatments.

Study Design/Materials and Method: A dorsal window chamber was surgically installed on 18 mice. Each animal was applied to one of the following experimental groups: saline alone (negative control), oxymetazoline alone (10 μL applied on daily basis), PDL alone [saline applied five minutes before PDL irradiation (10 mm spot size, 1.5 ms pulse duration, $7~J/cm^2$ delivered to epidermal side of the window), or oxymetazoline + PDL (10 μL oxymetazoline applied five minutes before PDL and then on daily basis). To monitor vascular architectural and functional changes, brightfield and laser speckle imaging were performed for seven days.

Results: With application of oxymetazoline, inconsistent changes were observed in vessel diameter. PDL alone at study settings resulted in an initial decrease but subsequent recurrence of flow at seven days post-irradiation. With oxymetazoline + PDL, a noticeable difference in vascular effects were observed at seven days: an increase in probability of vascular shutdown and a difference in vascular architecture (an increase in tortuous microvasculature that is suggestive of replacement of native larger vessels with smaller vessels via angiogenesis).

Conclusion: Oxymetazoline + PDL may enhance cutaneous vascular shutdown and should be explored as a combined treatment option for cutaneous vascular conditions including rosacea and port wine birthmarks.